Michael Okunewitch
Stock Analyst at Maxim Group
(0.25)
# 4,111
Out of 4,840 analysts
24
Total ratings
13.04%
Success rate
-22.57%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals | Maintains: Buy | $6 → $3 | $1.09 | +175.23% | 2 | May 15, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.20 | +185.71% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.36 | +414.71% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $2.04 | +586.27% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.65 | +358.72% | 1 | Jan 10, 2025 | |
| CTOR Citius Oncology | Initiates: Buy | $3 | $0.88 | +240.83% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.97 | +314.08% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.84 | +1,328.40% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.36 | +341.18% | 2 | Aug 27, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $1.08 | +1,011.11% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.15 | +1,986.23% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $3.11 | +479.71% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $3.55 | +56,942.25% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $20.10 | +24.38% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.62 | +270.37% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $160 | $8.21 | +1,848.84% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.99 | +1,156.28% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.70 | +14,185.71% | 1 | Nov 30, 2021 |
Anebulo Pharmaceuticals
May 15, 2025
Maintains: Buy
Price Target: $6 → $3
Current: $1.09
Upside: +175.23%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.20
Upside: +185.71%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.36
Upside: +414.71%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $2.04
Upside: +586.27%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.65
Upside: +358.72%
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $0.88
Upside: +240.83%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.97
Upside: +314.08%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.84
Upside: +1,328.40%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.36
Upside: +341.18%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.08
Upside: +1,011.11%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.15
Upside: +1,986.23%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.11
Upside: +479.71%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $3.55
Upside: +56,942.25%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $20.10
Upside: +24.38%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.62
Upside: +270.37%
Mar 24, 2022
Initiates: Buy
Price Target: $160
Current: $8.21
Upside: +1,848.84%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.99
Upside: +1,156.28%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.70
Upside: +14,185.71%